Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation

Blood

Volumn 103, Issue 8, 2004, Pages 2936-2938

  Palladini, Giovanni ^b   Perfetti, Vittorio ^b   Obici, Laura ^b   Caccialanza, Riccardo ^b   Semino, Alessandra ^b   Adami, Fausto ^b   Cavallero, Giobatta ^b   Rustichelli, Roberto ^b   Virga, Giovambattista ^b   Merlini, Giampaolo ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; MELPHALAN; PREDNISONE;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CYTOPENIA; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REMISSION; RESPIRATORY TRACT INFECTION; SIDE EFFECT; TREATMENT OUTCOME;

EID: 11144358046     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-08-2788     Document Type: Article

References (9)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583-596.
2. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;8:45-59.
3. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone and melphalan, prednisone and colchicine. N Engl J Med. 1997;336:1202-1207.
4. Sanchorawala V, Wright DG, Seldin DC, et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant. 2001;28:637-642.
5. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002;99:4276-4282.
6. Palladini G, Anesi E, Perletti V, et al. A modified high-dose dexamethasone regimen for primary systemic amyloidosis. Br J Haematol. 2001;113:1044-1046.
7. Merlini G, Marciano S, Gasparro C, et al. The Pavia approach to clinical protein analysis. Clin Chem Lab Med. 2001;39:1025-1028.
8. Palladini G, Malamani G, Cò F, et al. Holter monitoring in AL amyloidosis: prognostic implications. Pacing Clin Electrophysiol. 2001;24:1228-1233.
9. Seldin DC, Choufani EB, Dember LM, et al. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma. 2003;3:241-246.